X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DISHMAN PHARMA NATCO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 23.2 25.1 92.3% View Chart
P/BV x 17.6 3.3 524.4% View Chart
Dividend Yield % 0.7 0.7 98.1%  

Financials

 NATCO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DISHMAN PHARMA
Mar-16
NATCO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs877374 234.2%   
Low Rs424129 328.5%   
Sales per share (Unadj.) Rs223.4197.8 113.0%  
Earnings per share (Unadj.) Rs31.121.2 146.5%  
Cash flow per share (Unadj.) Rs40.334.7 116.0%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.8 96.8%  
Book value per share (Unadj.) Rs219.5179.9 122.0%  
Shares outstanding (eoy) m33.0780.69 41.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.3 228.8%   
Avg P/E ratio x20.911.9 176.4%  
P/CF ratio (eoy) x16.17.2 222.8%  
Price / Book Value ratio x3.01.4 211.8%  
Dividend payout %16.19.4 170.6%   
Avg Mkt Cap Rs m21,50420,306 105.9%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,1285,355 21.1%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m7,38915,961 46.3%  
Other income Rs m167265 63.0%   
Total revenues Rs m7,55616,226 46.6%   
Gross profit Rs m1,7934,103 43.7%  
Depreciation Rs m3041,091 27.9%   
Interest Rs m366944 38.8%   
Profit before tax Rs m1,2902,334 55.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309624 49.5%   
Profit after tax Rs m1,0271,711 60.0%  
Gross profit margin %24.325.7 94.4%  
Effective tax rate %23.926.7 89.6%   
Net profit margin %13.910.7 129.7%  
BALANCE SHEET DATA
Current assets Rs m3,68111,018 33.4%   
Current liabilities Rs m3,1239,517 32.8%   
Net working cap to sales %7.69.4 80.4%  
Current ratio x1.21.2 101.8%  
Inventory Days Days89110 81.0%  
Debtors Days Days5935 168.5%  
Net fixed assets Rs m7,68516,304 47.1%   
Share capital Rs m331161 204.9%   
"Free" reserves Rs m6,67012,907 51.7%   
Net worth Rs m7,25914,516 50.0%   
Long term debt Rs m9554,189 22.8%   
Total assets Rs m11,95729,805 40.1%  
Interest coverage x4.53.5 130.3%   
Debt to equity ratio x0.10.3 45.6%  
Sales to assets ratio x0.60.5 115.4%   
Return on assets %11.78.9 130.8%  
Return on equity %14.211.8 120.1%  
Return on capital %20.717.5 118.2%  
Exports to sales %39.424.8 158.8%   
Imports to sales %5.73.7 152.6%   
Exports (fob) Rs m2,9083,956 73.5%   
Imports (cif) Rs m421596 70.6%   
Fx inflow Rs m3,4454,952 69.6%   
Fx outflow Rs m703697 100.9%   
Net fx Rs m2,7434,255 64.5%   
CASH FLOW
From Operations Rs m1,4402,786 51.7%  
From Investments Rs m-1,089-1,529 71.2%  
From Financial Activity Rs m-353-941 37.5%  
Net Cashflow Rs m-1316 -0.5%  

Share Holding

Indian Promoters % 52.0 61.4 84.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 12.7 130.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 22.1 117.6%  
Shareholders   25,395 46,261 54.9%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   TORRENT PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS